Cargando…
Alternative Complement Pathway Inhibition Does Not Abrogate Meningococcal Killing by Serum of Vaccinated Individuals
Dysregulation of complement activation causes a number of diseases, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. These conditions can be treated with monoclonal antibodies (mAbs) that bind to the complement component C5 and prevent formation of the membrane a...
Autores principales: | Ispasanie, Emma, Muri, Lukas, Schubart, Anna, Thorburn, Christine, Zamurovic, Natasa, Holbro, Thomas, Kammüller, Michael, Pluschke, Gerd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531814/ https://www.ncbi.nlm.nih.gov/pubmed/34691058 http://dx.doi.org/10.3389/fimmu.2021.747594 |
Ejemplares similares
-
Alternative Complement Pathway Inhibition Abrogates Pneumococcal Opsonophagocytosis in Vaccine-Naïve, but Not in Vaccinated Individuals
por: Muri, Lukas, et al.
Publicado: (2021) -
In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway
por: Ispasanie, Emma, et al.
Publicado: (2023) -
Inhibition of the different complement pathways has varying impacts on the serum bactericidal activity and opsonophagocytosis against Haemophilus influenzae type b
por: Muri, Lukas, et al.
Publicado: (2022) -
Characterization of vaccine antigens of meningococcal serogroup W isolates from Ghana and Burkina Faso from 2003 to 2009
por: Ispasanie, Emma, et al.
Publicado: (2014) -
Spontaneous point mutations in the capsule synthesis locus leading to structural and functional changes of the capsule in serogroup A meningococcal populations
por: Ispasanie, Emma, et al.
Publicado: (2018)